# Aqtual

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aqtual

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.aqtual.com
- Total disclosed funding: $47M
- Latest round: Series B (Jul 10, 2025)
- Investors on record: 5

## About

Based in California, US, and founded in 2018, Aqtual Inc. operates as a biotechnology research company that develops and manufactures precision medicine and equipment for the treatment and monitoring of cancers and chronic diseases. The company was founded by its CEO Diana Abdueva. In July 2025, Aqtual, Inc. raised USD 31 million in series B funding from new investors Bold Capital and BLG Advisor, with participation from returning investors Genoa Ventures, Manta Ray Ventures, and Yu Galaxy. The firm develops and produces precision drugs and devices for the monitoring and treatment of chronic conditions and cancers. It provides research and practical healthcare solutions and provides blood tests for disease detection, and monitoring. It offers healthcare solutions for inflammatory conditions, immunology, cardiovascular diseases, metabolic diseases, neurological conditions, etc. The company will use the July 2025 funding for further research and development.

## Funding rounds

- Series B, Jul 10, 2025, $31M — Bolder Capital, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, BOLD Longevity Growth fund
- Series A, Oct 31, 2023, $16M — Genoa Ventures, Manta Ray Ventures, Yu Galaxy

## Investors

- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A, Series B
- Manta Ray Ventures (https://capitalatlas.ai/funds/manta-ray-ventures) — Series A, Series B
- Yu Galaxy (https://capitalatlas.ai/funds/yu-galaxy) — Series A, Series B
- Bolder Capital (https://capitalatlas.ai/funds/bolder-capital) — Series B
- BOLD Longevity Growth fund (https://capitalatlas.ai/funds/bold-longevity-growth-fund) — Series B